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 THESIS ABSTRACT 
The growing burden of HIV and non- communicable disease (NCD) syndemic in Sub Saharan 
Africa, has necessitated introduction of integrated models of care in order to leverage 
existing HIV care infrastructure for NCDs. However, there is paucity of literature on long 
term treatment outcomes for multimorbid patients attending integrated care. We describe 
long term treatment outcomes among multimorbid patients who attended integrated ART 
and NCD clubs (IC), a novel model of care piloted in 2014 by the Western Cape Government 
in South Africa. 
 We followed up multimorbid patients for 12 months, who enrolled for IC at Matthew Goniwe 
and Town II clinics before September 2016.Median adherence proportions, HIV viral 
suppression and retention rates were calculated at 12 months before and after IC enrolment. 
Rates for achieving targets for blood pressure and glycosylated haemoglobin were 
determined at 12 months prior, at IC enrolment and at 12 months post IC enrolment. We 
describe demographic and clinical variables among all patients at IC enrolment and used 
multivariable logistic regression to evaluate for predictors of NCD control 12 months post IC 
enrolment. 
As of 31 August 2017, 247 patients in total had been enrolled into IC for at least 12 months.  
Of these, 221 (89.5%) had hypertension, 4 (1.6%) had diabetes mellitus and 22 (8.9%) had 
both in addition to HIV. Adherence was maintained before and after IC enrolment with 
median adherence proportions of 1 (IQR 1-1) and 1 (IQR 1-1) respectively. HIV viral 
suppression rates were 98.6%, 99.5% and 99.4% at the three time points respectively. 
Retention in care was high with 6.9% lost to follow up at 12 months post IC enrolment. 
Optimal blood pressure control was achieved in 43.1%, 58.9% and 49.4% of participants 
whereas optimal glycaemic control was achieved in 47.4%, 87.5% and 53.3% of diabetic 
participants at the three time points respectively. Multivariable logistic analyses showed no 
independent variables significantly associated with NCD control. Multi-morbid people living 
with HIV achieved high levels of HIV control in integrated HIV and NCD clubs. However, 
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ASSESSING THE EFFECTIVENESS OF INTEGRATED HIV AND NON-COMMUNICABLE DISEASE 
ADHERENCE CLUBS IN CAPE TOWN, SOUTH AFRICA. 
Investigators: Blessings Gausi; Natacha Berkowitz; Nisha Jacob; Tolu Oni 
1. Background and rationale 
South Africa has one of the world’s largest HIV burdens, with an HIV prevalence of 12.7%[1]. 
Consequently, it hosts the largest antiretroviral  treatment(ART) programme in the world[2], 
with 3.4 million patients receiving ARV care at no individual cost[3].  Since the advent of 
effective ARVs, HIV has become a chronic, manageable illness, with lifespans approaching 
that of HIV-uninfected persons[4]. This increased lifespan, along with the aging effect of HIV 
and drug interactions[5,6], has resulted in people living with HIV (PLHIV) to be at risk of 
developing lifestyle related non-communicable diseases (NCDs), thus increasing the burden 
of multi-morbidity (MM). 
Previous research has shown that there is a significant burden of MM in South Africa with 
prevalence estimates ranging from 22.6% to 48.4%[7,8]. This dual epidemic of 
communicable and non-communicable diseases will put strain on the current health system 
which is ill equipped to cope with the inherent complexity of MM patients[9]. 
NCD care has in large been neglected at a primary care level and this has been shown through 
poor patient outcomes. A large study from the Western Cape Province, sampling from 18 
primary care clinics, showed that over 60% of  people with hypertension  and  over 50% of 
people with diabetes attending primary care facilities had poorly controlled diseases[10]. 
HIV/TB and NCD care services are segregated in primary health care facilities in South Africa, 
which has resulted in inefficient care for multi-morbid patients, who have to attend multiple 
appointments at health facilities to receive care for all their conditions. 
To address the inadequacies of the current health system, South Africa is undergoing 
complete health care reform with the planned implementation of the National Health 
Insurance (NHI) over the next 10 years[11]. Within this framework is the re-engineering of 
Primary Health Care (PHC) and the development of the ideal clinic. One of the cornerstones 
of this restructuring is the creation of integrated health facilities[12], where all healthcare 
needs are addressed at a single access point. To accomplish this, innovative methods of 
health care delivery are needed. 
The most prevalent NCDs seen at health care facilities in the Western Cape (the setting of 
this study), are hypertension (HTN) and diabetes (DM)[13]. Two surveys conducted 
amongst the urban Black population of the Cape Town found the prevalence of hypertension 
and diabetes to be 35.6% [14]and 13.1%[15] respectively. 
Both HTN[16] and DM[17] have been associated with HIV-infection. A study investigating 
MM in Khayelitsha, a peri-urban settlement in Cape Town, found a high prevalence of 
comorbid hypertension and diabetes associated with HIV amongst patients on ARVs[8]. This 
high comorbidity highlights the need to integrate care of these conditions along with routine 
ARV management. 
 To achieve integration, a novel model of care that uses community adherence clubs that 
integrate HIV and NCD care (ICs), has been piloted at some clinics in Cape Town. This model 
involves both task shifting and decentralization of care at primary health care level. Each IC 
consists of 25-30 people living with HIV having been on ARVs for more than 6 months with 
suppressed viral loads (VL) and a diagnosis of NCD (DM, HTN or both). PLHIV without NCD 
diagnosis attend ordinary ART medical adherence clubs (MACs) which operate just like ICs 
except that only ART care is provided in these clubs. MACs have been shown to decongest 
facilities[18], improve retention in care[19], maintain virologic suppression[20], be cost 
effective[21] and be acceptable to both patients and health care workers[22].  
While the effectiveness of the MACs has been well described, there has not been a formal 
evaluation of the clinical effectiveness of the ICs since its adoption in Cape Town, South 
Africa. Studies done elsewhere have assessed the feasibility and clinical benefits of 
integrating vertical NCD and HIV care services in primary health care clinics intended for 
patients with either diagnosis[23,24,25,26]. To our knowledge, no study has been done in 
this setting  to assess the clinical effectiveness of integrating NCD and HIV care specifically 
for patients with multi-morbidity. 
2. Study aims and objectives 
This study aims to assess clinical outcomes in multi-morbid patients with HIV and comorbid 
DM and/or HTN after 12 months of receiving integrated care through integrated NCD and 
ART adherence clubs (IC) at two primary health care clinics in Cape Town. 
The objectives of the study are: 
1. To assess adherence to scheduled appointments for 12 months prior to, and 12 
months post IC enrolment. We hypothesize that IC enrolment improves or maintains 
adherence to scheduled appointments. 
2. To compare HIV viral loads (VL), blood pressure (BP) and haemoglobin A1c (Hba1c) 
control at around 12 months prior to IC enrolment, at enrolment into IC and around 12 
months after enrolment into IC, at the two clinical sites. We hypothesize that IC 
enrolment maintains or improves clinical control of comorbidity. 
3. To investigate factors that are associated with clinical control of co-morbidity in 
patients enrolled in IC in addition to IC enrolment. 
3.  Methods 
3.1  Study design 
We will conduct an analysis of data collected from a study that is already completed. These 
data were collected by Dr Berkowitz under supervision from A/Prof Oni. The study used an 
ambivalent design (i.e. partly retrospective and partly prospective cohort design), to enrol 
all HIV-infected adult patients with HTN or DM or both from three clinics (Mathew Goniwe 
and  Town II Primary Health Care facilities ) in Cape Town who attended IC appointments 
before September 2016. It is an observational cohort study. 
3.2  Study population and set up 
Data were collected from patients receiving integrated care at Mathew Goniwe and  Town II 
Primary Health Care facilities under the governance of the City of Cape Town Health 
Department. Mathew Goniwe and Town II are facilities based in the peri-urban township of 
Khayelitsha. They provide, along with 11 other facilities, general, paediatric, HIV and TB care 
to a predominantly Black African (99%) population. The total Khayelitsha population is 
approximately 500 000[27]. In 2013, the City of Cape Town had an estimated antenatal HIV 
prevalence of 19.7%[28]. This prevalence varies by district with, in 2011, Khayelitsha (under 
which the two facilities fall) having an antenatal prevalence of 37.1%. 
 
 
The following were inclusion criteria for the study: 
• Documented HIV positive status 
• Diagnosis of DM or HTN 
• Attending IC at the two Primary Health Care Clinics (Mathew Goniwe and 
Town II) before September 2016 
• Aged 18 years or more 
Comorbid patients who attend IC receive ART and NCD care simultaneously whereas the 
standard of care for a CAC attendee who has comorbid NCD comprises of attending a CAC 
club for ART care and a different outpatient appointment for NCD care. Figure 1 describes 
these care options. For those receiving standard of care, appointments are often on a 
different day to the CAC appointment, and may even be at a different facility. NCD care is 
offered by both medical officers and professional nurses.  
Figure 1: Description of care options for patients with comorbid NCDs and stable HIV at 
Primary Health Care Clinics in Cape Town. 
 
*NCD and HIV care occur simultaneously in the club setting 



















To help fully understand similarities and differences in terms of clinical care provided in 
CACs and ICs, we show clinical procedures undertaken in both adherence clubs in Table 1 
below. 
Table 1: Adherence club procedures 
 ARV adherence club (CAC) Integrated Club (IC) 
Club formation Approximately 25 patients are recruited into a club 
simultaneously and initiated into the club process 
together. 
Club admission criteria HIV infected: 
Stable – at least 6 
months on ARVs 
and suppressed 
viral load ( VL) 
HIV + DM and/or HTN  
Stable – at least 6 months 
on ART and suppressed VL. 
Blood pressure (BP) 
<140/90 mmHg; HbA1c† 
<9% if diabetic  
Number of Club visits per 
year 
Total = 5  
• 3 medication collections 
• 1 medication collection and clinical examination 
• 1 medication collection and phlebotomy 
Bloods tests conducted at 
phlebotomy visit  
Viral Load and safety 
bloods  
(Liver function, renal 
function and full blood 
count depending on ARV 
regimen) * 
Viral Load and safety 
bloods 
(Liver function, renal 
function and full blood 
count depending on ARV 
regimen 
HbA1c) **  
Creatinine ** 
 
Procedures at each clinical 
visit 
Weight, BP, Tuberculosis symptoms screen and ARV side 
effects screen, HIV and health education and adherence 
counselling at each visit by lay-counsellor***  
Staff providing care Lay-counsellor for medication collections 
Professional Nurse practitioner for clinical examination 
and phlebotomy 
Medical officer to review complicated patients 
†HbA1c = glycosylated haemoglobin 
*Based on provincial ARV guidelines[29] 
**Based on Primary Care “PACK” guidelines[30] 
***No specific NCD counselling for comorbid patients provided. 
 
3.3  Sampling and sample size calculation 
Sampling: All adult patients who attended IC at the two pilot sites and met the inclusion were 
enrolled (N=247). As the entire population of eligible participants was recruited, there was 
no sampling conducted. Patients with comorbid HTN and/or DM were identified from the 
club registers and clinic folders. Outcome measures (BP, VL, and HbA1c) were extracted from 
these comorbid patients’ medical records. 
Statistical power: No studies have been done to look at clinical effectiveness of IC care for 
patients with comorbidity.  We will therefore use data for all patients enrolled into IC to 
maximize power. 
3.4  Data collection 
Data were extracted from electronic and paper records that consisted of routinely collected 
data from patient visits. Data were captured directly onto a RedCap electronic database by 
the study team. All data were anonymized, and participant identification numbers used in 
place of personal patient details. 
Basic patient characteristics, as well as variables that may independently affect the outcome 
(clinical control of HIV, HTN and DM), were extracted from routinely collected data. These 
variables are shown in Tables 2. Clinical and adherence variables were also extracted. These 
are shown in Tables 3 and 4 respectively.   Other variables which have been found to 
independently affect HTN and DM control such as income, level of education[31] and lifestyle 
related factors (smoking, diet and exercise)[32] were not available from routinely collected 
patient data and hence were not included in data collection. This will be acknowledged in 
analysis as well as in limitations of the study. 
 
Table 2: Independent variables 
Variable Format Description 

















Weight* Continuous Kilograms 
Height* Continuous Centimetres 









Date of commencement of 
ARVs 
dd/mm/yyyy  
Date of HIV diagnosis dd/mm/yyyy  
Date of NCD 
diagnosis/diagnoses 
dd/mm/yyyy  
Date of entry into integrated 
club 
dd/mm/yyyy  
CD4 count at HIV diagnosis 
Numerical 













Table 3: Clinical outcome variables (at around 12 months prior, IC entry and 12 months post 
IC entry) 







(Blood pressure <140/90)  
Categorical No  
Yes 
HbA1c Numerical % 




Viral Load Numerical >1000 copies/ml 














Table 4: Adherence variables 
Variable Format Description 
Number of missed 
medication collection visits 1-
year before IC enrolment 
 
Numerical  
Number of missed club visits 
1-year post IC entry 
Numerical  
Good adherence (collection of 
medication≥ 80% 1-year 
before IC enrolment) 
Categorical Yes 
No 
Good adherence (club 
attendance 1-year after IC 
enrolment) 




3.5  Measurement 
Attendance definition 
Attendance over one year prior to IC enrolment and one-year post IC enrolment was 
recorded (see Table 4 above). Prior to IC enrolment, we will use medication collection as a 
surrogate for adherence as the participant’s attendance schedule would have been variable. 
After IC enrolment, adherence to club visits was collected from club registers (sheets on 
which club patient visits are documented). Good adherence will be defined as adherence of 
>80%[33] (medication collection or club attendance). An acknowledged limitation to this 
analysis will be the lack of individual participant data on reasons for non-attendance, such 
as travel, illness or accessing private health care, which may affect the outcome. 
Outcome measurement 
Clinical outcome variables consist of BP, HbA1c and VL. These were extracted at 12 months 
before IC entry, at IC entry and 12 monthly for VL and HbA1c, and at IC entry and 6 or 12- 
monthly (dependent on facility) for BP (Table 3 above). Figures 3 – 5 describe when each 
outcome variable was collected for each patient category, that is, patients with HIV, DM and 
HTN (HIVDMHTN), HIV and DM (HIVDM), and HIV and HTN (HIVHTN) respectively. 
 



























IC entry and 
12 monthly
HbA1c




Clinical control definition: 
Patient outcomes were assessed until 31 August 2017 (closure of data collection).  HTN 
control was defined as having the last BP reading  of <140/90mmHg[34]  12 months after IC 
enrolment and compared with HTN control at IC entry. DM control will be defined as the last 
HbA1c of <7.5%[35] 12 months after IC enrolment and compared with DM control at IC 
entry. Participants will be defined as virally suppressed if viral load is <1000 copies/ml [29] 
12 months after IC enrolment. 
3.6  Data Analysis plan 
 Participant data from all sites will be pooled for the purposes of analysis. Participant 
characteristics will be described using tables and figures. Categorical data will be described 








IC entry and 
12 monthly
BP
IC entry and 
6/12 monthly
described using means and confidence intervals, while medians and interquartile range will 
be used for non-parametric data. Significance testing will be conducted using 2-sided p-
values at α of 0.05. 
Objective 1: Assessing adherence to scheduled appointments for around 12 months prior to, and 
12 months post IC enrolment.  
Adherence to scheduled appointments will be determined by calculating the proportion of 
appointments attended for every participant during the study period. Mean adherence 
proportions will be calculated prior to IC enrolment and post IC enrolment. These will be 
compared using a paired t-test under the null hypothesis that IC enrolment improves 
adherence to care in general. 
Objective 2: Clinical outcomes analysis 
For the purposes of this analysis, a participant will be deemed clinically controlled if and only 
if both of their clinical diagnoses are controlled i.e. both HIV and NCD where NCD shall mean 
HTN, DM, or both. We will calculate the proportion of comorbid participants controlled at 12 
months before IC enrolment, at IC enrolment and 12 months after IC enrolment. We will 
compare them using Chi-squared test for trend and Fischer’s exact test as appropriate under 
the null hypothesis that IC enrolment improves or maintains clinical control of comorbidity. 
The primary exposure variable will be IC enrolment whereas comorbidity control will be the 
outcome variable.  
 
 
Objective 3: Investigating factors that are associated with control of co-morbidity 
We will use logistic regression to determine factors that could have additionally affected 
clinical control of HTN, DM and HIV other than IC enrolment.  
Outcome variable: To preserve power in a multivariate model, we will collapse control of 
comorbidity into one outcome variable. We will model this response variable as 1 if both HIV 
and DM, or HIV and HTN or HIV and both DM and HTN are all optimally controlled at around 
12 months post IC entry and as 0 if otherwise. 
 Predictors of clinical control:  We will perform bivariate analyses to assess potential factors 
at IC entry that independently affected clinical control 12 months post IC entry. The following 
variables will be assessed: age, sex, WHO stage(I,II,III,IV) at ART initiation, BMI(< 18.5,18.5≤ 
and <25,25≤ and <30, and >30 using WHO classification of BMI[36]),duration of ART(< 1-
year,≥1-year),duration of HIV diagnosis(<1-year and ≥1-year),good adherence(Yes/No), 
CD4 count at diagnosis(<500 and ≥500) and clinic site(Matthew Goniwe and Town II.  A 
student’s t-test, Mann–Whitney U test as well as Pearson’s χ² and Fischer’s exact test will be 
performed where appropriate. The univariate analyses will be shown in dummy Table 5 
below. 
 Table 5: Predictors for clinical control apart from IC enrolment 
Variable Clinical control (Yes)  Clinical control (No) P value 
Age (mean± SD)    
Sex(%Male)    
WHO stage 
I     
II    
III    
IV    
BMI category 
BMI< 18.5    
18.5≤ BMI<25    
25≤ BMI <30    
ART duration 
< 1-year    
≥1-year    
 Duration of HIV diagnosis 
< 1-year    
1-5 years    
> 5 years     
Good adherence 
Yes    
No    
IC enrolment 
Yes    
No    
Clinic site 
Town II    
Matthew Goniwe    
 
We will calculate crude odds ratios   and conduct univariate logistic regression to identify all 
independent variables that yield a p-value of ≤0.2. These variables will be used in model 
building to estimate adjusted odds ratios and 95% confidence intervals for variables 
associated with clinical control.  
Model building: We will build the multivariable logistic regression model manually and using 
a step-wise approach. Predictors with p-value ≤ 0.2 in univariate analyses will be selected 
for building the multivariable model. We will perform a Pearson’s test for goodness of fit to 
ascertain model fit. Other variables that improve model fit with the data using the Pearson’s 
test for goodness of fit will also be considered in the multivariable model.  
Results from the multivariate logistic model will be shown in dummy Table 6 below. 
All statistical analyses will be conducted in STATA 15.0 (Stata Corp LP, College Station, TX). 
 
Table 6: Factors significantly associated with control of comorbidity 
Variable OR (95 %CI) P Value Adjusted OR P- Value 
     
     
     
 
4. Ethical Considerations 
We plan to conduct an analysis of data that was already collected. Ethical approval for the 
primary study was obtained from The University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee (HREC reference number 085/2017) as well as the 
Provincial Health Research Ethics Committee prior to data collection. 
4.1  Minimizing harm  
The primary study involved collection of data from patient paper and electronic records. 
That imposed minimal harm to the participants as all data were anonymized and all unique 
patient identifiers (such as names or identification numbers) were removed.   This study 
will analyse the anonymized and de-identified data. 
4.2  Benefit 
There is no direct benefit to individual participants from which data was primarily collected. 
However, if the IC are found to be effective in managing stable comorbid patients, they may 
be implemented at more facilities, improving health care for the greater population. 
4.3  Confidentiality 
During primary data collection, participants were assigned study patient identifiers and 
entered in Redcap database that is password protected and access controlled by the 
primary investigator in order to ensure confidentiality.  In this study we do not anticipate 
any breach of confidentiality since the data to be analysed is already anonymised  
 
Since this study involves no anticipated harm to participants in the primary study, we 
therefore plan to obtain expedited ethical approval from the University of Cape Town Human 
Ethics Committee as part of good practice in  ethical conduct of research as stipulated by the 
Declaration of Helsinki[37]. Data from the study will be kept for one year after primary 
analysis to allow for manuscript preparation and publication. 
5. Dissemination of Results 
Integration of health care is part of the mandate of the NHI. This study will provide an 
evaluation on a proposed model of care that may benefit patients, health care workers and 
facilities. Results will be reported to the facilities and adherence clubs involved, as well as 
dissemination to local authorities to guide systems planning.  Results will also be 
disseminated to the academic audience locally and internationally through conference 
proceedings and peer-reviewed publications. 
6. Logistics 
Study Timeline: 
 June  July August September October November December 
Ethical approval        
Data Analysis        
Write-up and 
dissemination 
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PATIENT OUTCOMES IN INTEGRATED HIV AND NON-COMMUNICABLE DISEASE 
MODELS OF CARE: A SCOPING REVIEW  
Abstract 
Background: High rates of non-communicable diseases (NCD) among people living with HIV 
have been reported in high HIV burden, low-resource settings. The growing burden of HIV 
and NCD syndemic has necessitated introduction of integrated models of HIV and NCD care 
in order to leverage existing HIV care infrastructure for NCDs. There is a paucity of evidence 
on the effects of integrated care on long-term patient outcomes.  We sought to review 
literature that described effects of integration on long-term patient outcomes. 
Design: Scoping review 
Methods: We reviewed literature published between 01 Jan 2000 to 25 September 2019, 
that described long-term patient outcomes in HIV and NCD integrated models of care in 
order to understand the effects of integration on long-term patient outcomes. Relevant 
literature was searched in PubMed, Scopus, EBSCOhost and Web of Science. A manual search 
of abstracts in the International AIDS Society and the Journal of Acquired Immunodeficiency 
Syndrome was also conducted. 
Results: One thousand six hundred and sixty (1660) articles were identified, 31 of which 
were read in full, with 11 meeting our eligibility criteria. Patient outcomes in four models of 
integrated care were identified: i) integration of NCD screening and treatment services into 
established HIV centres; ii) integration of HIV screening and treatment services into 
established NCD centres; iii) simultaneous integration of HIV and NCD services at health 
facilities and iv) integrated HIV and NCD care specifically for multi-morbid patients. Studies 
reported high rates of control of HIV and NCD across the various models of integrated care. 
However, the majority lacked comparator groups required to ascertain superiority of 
integrated care over non-integrated care. 
Conclusion: There is limited evidence on the effect of integration on long-term patient 
outcomes especially in low-resourced and high-burden settings. Well-designed clinical trials 
with defined comparator groups are needed to demonstrate superior benefit of integrated 
care over non-integrated care. 




Human Immunodeficiency virus (HIV) is a threat to global public health with almost 40 
million people living with the virus worldwide[38]. With the advent and scale up of anti-
retroviral therapy (ART), HIV has become a manageable chronic condition with life 
expectancies of people living with HIV (PLWH) comparable to those living with other chronic 
conditions[4]. This increasing longevity among PLWH, and the premature aging effect of HIV 
is increasing the prevalence of non-communicable disease (NCD) comorbidities such as 
Diabetes Mellitus Type 2 (DM) and hypertension (HTN)[5],[6]. High rates of NCDs among 
PLWH have been reported in high HIV-burden, and low-resource settings[7],[8],[39] placing 
strain on the health systems  in these settings  which are  ill equipped to cope with the 
inherent complexity of multi-morbid patients[9].  
The growing burden of HIV and NCD syndemics has necessitated exploration of integration 
of HIV and NCD care in primary health care to leverage existing HIV care infrastructure for 
NCD care in high HIV-burden settings[40],[41]. Integrated care has been defined as the 
coordination, co-location, or simultaneous delivery of HIV and NCD services to patients who 
need it, when they need it[42]. Three models of integrating HIV and NCD care in primary 
health care have been previously described[43] as follows: Model 1: Integration of NCD 
screening and treatment services into established HIV centres; Model 2: Integration of HIV 
screening and treatment services into established NCD centres; and Model 3: simultaneous 
integration of HIV and NCD services at integrated health centres. As these models do not pre-
suppose multi-morbidity, a fourth model proposed by Njuguna et al[40] includes integrated 
HIV and NCD care for PLWH with comorbid DM or HTN or both, which may be delivered at 
group (using medical adherence clubs-MACs) or individual levels. 
Despite the increasing evidence to suggest feasibility of integrating HIV and NCD care, little 
is known about the effect of such integration on long-term patient outcomes[40,43,44]. 
These long-term outcomes include, but are not limited to, medication adherence, retention 
in care, loss to follow up, HIV viral load suppression/ improvement in CD4 counts and NCD 
control. It is not known if integration of HIV and NCD care in primary health care improves 
or at least maintains these outcomes among PLWH receiving integrated HIV and NCD care. 
Such evidence is needed to inform program managers and health policy makers in order to 
adopt, implement and scale up integrated HIV and NCD care for multi-morbid patients. 
This review aims to identify literature that describes the effect of integrating HIV and NCD 
care on long-term patient outcomes.  
2. Methods  
We conducted a scoping review[45],[46] of literature that described the effect of integrating 
HIV and NCD care on long-term patient outcomes. This review followed the Arksey and 
O’Malley methodological framework for conducting scoping reviews which comprises 5 
stages: identifying the research question, identifying relevant studies, study selection, 
charting the data and collating, summarizing and reporting results[47],[48]. 
2.1  Research question 
 This review was guided by the question ‘What are the effects of integrating HIV and NCD 
care on long-term patient outcomes?’ 
2.2  Search strategy 
 We conducted a preliminary search of the terms ‘outcomes, effects, successes, effectiveness, 
impact, integrated HIV, non-communicable disease, chronic disease care’ in PubMed. We 
then sifted through key studies for potential broader search terms and refined the search 
strategy (Table 1). 
 Table 1: Search strategy applied to PUBMED and adapted for use in other databases 
Query Fields Search term  
#1 All Effects OR outcomes OR effectiveness OR Successes OR impact 
#2 All (Integrated OR combined) AND (care OR management OR health service 
delivery model) 
#3 All Chronic disease OR Non-communicable disease  
#4 All  HIV OR Human Immunodeficiency Virus 
#5 #1 AND #2 AND #3 AND #4 
 
2.3  Information sources 
We performed a literature search, using the final search strategy in PubMed, Scopus, 
EBSCOhost and Web of Science. We also conducted a manual search of abstracts in the 
International AIDS Society and the Journal of Acquired Immunodeficiency Syndrome. Grey 
literature was sourced from Mednar and Open Grey. Bibliographies of relevant papers were 
also carefully searched to source journal articles unidentified through database searches. 
2.4  Inclusion criteria 
We included articles that reported at least one of the following patient outcomes after 
receiving integrated care for at least 6 months: adherence to medication, retention in care, 
loss to follow up, viral load measurements, CD4 counts and markers of NCD treatment 
outcomes including blood pressure (BP) for HTN, and glycosylated hemoglobin (HBA1c) for 
DM.  
Inclusion criteria for this review included patients older than 18 years of age enrolled into 
integrated care, with a diagnosis of either HIV alone, HIV and HTN or HIV and DM or both. 
Longitudinal studies, case-control and cross-sectional studies published between 01 Jan 
2000 to 25 September 2019 were included for review. This time frame was selected as there 
was little wide spread roll-out of ART programs in low- and middle-income countries, where 
the burden of HIV is highest, prior to 2000.   
2.5  Exclusion criteria 
Literature not published in English and did not report patient outcomes of interest was 
excluded. Literature reviews were also excluded; however, their reference lists were 
carefully searched for eligible studies. 
2.6  Study selection 
Articles retrieved using the search strategy were exported into EndNote version 9 for 
removal of duplicates. Thereafter, two authors (BG and PO) independently screened articles 
by title or title and abstract to determine if articles met the eligibility criteria. A full-text 
screening was then carried out. Ambiguous abstracts were also evaluated via a full text 
review for eligibility. Disagreements between the two reviewers were resolved through 
discussion to reach consensus. 
2.7  Ethical considerations 
As reviewed literature were published and available in the public domain, ethical approval 
was not sought for the purposes of conducting this review.  
2.8  Data collection and synthesis 
The following outcomes were collected and charted from selected articles using a 
standardized form: author, place, setting of intervention/study, model of integration utilized, 
intervention (services integrated), duration of intervention, study population, and results 
(Table 2). A narrative synthesis of the results was also performed on included studies. 
3. Results  
A total of 11 studies were included in the review. Results of our search strategy and process 




















































PubMed (n =42) 
EBSCOHOST (n= 41) 
Web of Science (n=28) 
Scopus (n= 338) 
Mednar (n= 582) 
Manually hand searched in JAIS (n= 
129) and JAIDS (n= 545) 
Reference lists (n=3) 
Total Records identified  










































Duplicates removed (n=48) 
Titles and abstracts screened  
(n=1660) 
 
Records excluded in screening 
(n=1629) 
These articles were excluded because 
they were not related to integrated 




Full-text articles assessed 
for eligibility (n=31) 
• Full-text articles excluded for not 
reporting any of the outcomes of 
interest (n=17) 
• Literature reviews (n=3) 
 
 
Studies included  
(n=11) 
3.1  Characteristics of included studies 
Ten of the eleven studies included were full text articles[23,49–57] whereas  one was an abstract 
article[58].Eight studies (72.7%) were published later than 2010 and the majority (n=7), were 
cohort studies (Table 2). There were no randomized clinical trials identified. Six of the 11 studies 
were conducted in developed countries (United States of America and United Kingdom) with 5 
conducted in low and middle income high HIV-burden countries (Cambodia, Uganda, Kenya and 
South Africa) (Table 2).  
3.2  Models of HIV/NCD integration 
Applying the 4 model categories described by Duffy and Njuguna[40],[43], 3 of the 8 studies 
identified describe NCD services integrated into established HIV care centres (model 1), 5 describe 
simultaneous integration of HIV and NCD services (model 3), and 3 studies reported integration 
of HIV and NCD services for multi-morbid PLWH (model 4). No studies reported integration of 
HIV services into established NCD programs (model 2) (Table 2). 
3.3 Patient outcomes 
All studies reported HTN outcomes, 60% reported DM outcomes and 50% reported HIV 
outcomes. Only Janssens et al [51], reported patient outcomes for all three diseases (Table 2). Eight 
of the 11 studies (72.7%), reported integrated care based in primary care facilities (Table 2). 
3.3  Patient outcomes by model of integration 
Model 1: Integration of NCD services into established HIV care centres  
The 3 studies that reported patient outcomes in the context of integration model 1,[49,50,57] 
offered NCD screening and treatment services to PLWH. Prevalence of comorbid HTN among 
PLWH studied was 26% (USA), 47.8% (Uganda) and 43% (USA) respectively[49],[50],[57]. Chu 
et al[49] conducted a descriptive cross-sectional study among PLWH with comorbid DM or 
comorbid HTN. They found that 90% (N= 223) of PLWH with comorbid HTN had controlled BP 
(BP ≤140/90) and 59% (N= 103) of PLWH and DM had achieved glycaemic control (HbA1c < 
7%). However, HIV related outcomes such as HIV viral suppression or CD4 counts, were not 
reported.  
Muddu et al[50]  compared HIV control rates among PLWH with no co-morbidity to PLWH with 
comorbid HTN. They found that after 1-year of follow up, 24.3% of those with comorbid HTN 
(N= 218) had controlled BP. HIV-related outcomes and retention rates did not differ between 
PLWH without (viral load (VL) suppressed in 90.2%; retention 71.4% (N=906)) or with comorbid 
HTN (VL suppressed in 91.6%; retention 65.9% (N=218)) respectively. Myerson et al[57] 
conducted a cross-sectional study in the USA examining control of HIV and HTN among PLWH. 
They found that among PLWH with comorbid HTN, 57% (N=1840) had controlled BP. In terms 
of HIV control, 88% of the overall cohort (N= 4278) were on ART and 67% of these had 
suppressed VL (mean CD4 count 468 cells /µL). 
 While these studies reported high rates of control of HIV and comorbid NCDs among patients 
who received model 1 of integrated care, they were not designed to show benefit of integrated care 
compared to non-integrated care. Instead, they merely   reported patient outcomes upon integrating 
NCD screening and treatment services in established HIV programs. Comparison was not made to 
patient outcomes either before integration or in non-integrated care. 
Model 3: Simultaneous integration of NCD and HIV services  
Five studies reported patient outcomes upon simultaneous integration of HIV and NCD 
care[23,51–54]. Full details on study design, integrated services and results are shown in Table 2. 
Janssens et al[51] report treatment outcomes from 8850 participants receiving integrated care for 
24 months. Of the 8850, 1419 were HIV-uninfected and received care for HTN only, 2638 were 
HIV-uninfected and received care for DM only and 4793 were PLWH without comorbidities. 
Among PLWH, 87.7% (N=4793) were retained in care ,9.3% had died with 3% lost to follow up. 
Median CD4 counts after 24 months of attending integrated care rose from 53 to 316 cells/mm3. 
However, viral suppression rates were not reported. Among people with HTN, 68% (N=1419) had 
controlled BP. Among people with DM, median HbA1c fell from 11.5% to 8.6% while 57% had 
HbA1c ≤ 9%.  
Khabala et al[52] conducted a descriptive retrospective  cohort study of 1432  HIV-infected and 
uninfected participants. Of the 1432, 1020 were HIV infected, 352 were HIV-uninfected with HTN 
whereas 60 were HIV-uninfected with DM. Participants were clinically stable for at least 12 
months and recruited into MACs of 25-30 patients each. They reported an overall loss to follow 
up of 3.5% and high rate of compliance to clinical procedures, however, patient outcomes related 
to control of HIV or NCD were not reported. 
 Kwarisiima et al[53]  conducted a descriptive cohort study which examined BP control among 
people with HTN without HIV and PLWH with comorbid HTN in a rural Ugandan community. 
After screening 34,704 individuals for HIV and HTN, 2071 had HIV while 4355 had HTN without 
HIV. Of the 4355, 1949 were linked to care at baseline whereas of the 2071 PLWH,199 had 
comorbid HTN and only 89 were linked to care at baseline. Control of BP among PLWH with 
HTN (48%) and people with HTN only (46%) did not differ. In this study, authors noted that NCD 
care was interrupted with significant stock outs for hypertension drugs during the study which may 
have affected clinical outcomes. Of note, investigators observed that HIV-infected patients were 
more likely than uninfected patients to have controlled BP at follow-up visits (aOR 1.28; 95% CI 
1.00–1.77). 
 Ameh et al[23] conducted a controlled interrupted time series study in rural South Africa that 
compared the likelihood of control of HIV and HTN before and after a pilot implementation of an 
integrated chronic disease management (ICDM) model by the National Department of Health in 
selected primary health care facilities.  A sample of 435 participants were enrolled in intervention 
facilities using proportionate sampling of which 210 had HTN and 141 were PLWH. Similarly, a 
sample of 443 participants were enrolled in control facilities in which 91 had HTN and 282 were 
PLWH. Results showed that after 30 months of follow up, patients at intervention facilities had a 
6% greater likelihood of having CD4 counts >350 compared to control facilities (coefficient = 
0.057; 95% confidence interval: 0.056-0.058; P < 0.001). In addition, patients at pilot facilities had 
a 1.0% greater likelihood of having patients with controlled BP (coefficient = 0.010; 95% 
confidence interval: 0.003 to 0.016; P = 0.002). However viral suppression, retention in care and 
loss to follow up were not reported.  
The last Model 3 study was conducted by Edwards et al[54], at a primary care center in an urban 
informal settlement in Kenya. This was a retrospective descriptive study of 2206 participants that 
compared BP and diabetes outcomes among PLWH with comorbid HTN (N=200) or DM (N=10), 
with people living with only HTN (N=1697) or only DM (N=299). At 30 months of follow-up, the 
median systolic blood pressure (SBP) reduced from 151 (Interquartile range (IQR) 136-164) 
mmHg at baseline to 143 (IQR 129-159) mmHg, while diastolic blood pressure (DBP) reduced 
from 97 (IQR 86-105) mmHg to 85 (IQR 74-95) mmHg for PLWH and comorbid HTN. For people 
living with HTN only, median SBP reduced from 160 (IQR 144–177) mmHg at baseline to 141 
(IQR 129–158) mmHg while DBP reduced from 100 (IQR 90–110) mmHg to 87 (IQR 75–95) 
mmHg. For PLWH and DM, mean HbA1c at last visit was 8.2% while among people with DM 
only, mean HbA1c at last visit was 8.8%. Neither HbA1c at baseline nor HIV outcomes were 
reported.  
In summary, control of HIV and comorbidities was achieved in this model of care despite logistical 
challenges experienced by some. Majority of studies describing this model of care did not report 
key HIV-related outcomes such as viral suppression. Only one study (Ameh et al[23]) compared 
outcomes among patients who attended integrated care with those who attended non-integrated 
care. The study showed some evidence that patients who attended IC were more likely to have 
controlled HIV or NCD compared to non-integrated care patients, suggesting superiority of IC 
over non-integrated care for control of morbidities.  Besides that, the rest of the studies did not 
have comparator groups. 
Model 4: Integrated care for multi-morbid patients 
Three studies reported patient outcomes in model 4 of integration[55],[56],[58] (Table 1). Two of 
these studies (Bury et al[55] and Oluwatoyin et al[56]) undertook descriptive retrospective cohort 
studies  among PLWH with comorbid DM who attended integrated care at HIV specialist clinics 
in the USA. At the end of follow up, Bury et al[55]  and Oluwatoyin et al[56] report that 50% and 
54% of participants respectively, had achieved American Diabetes Association targets for BP (< 
140/90) and HbA1c (<  7%)[59] at last visit. These outcomes were found to be similar to those in 
studies with HIV-uninfected populations in the same setting[60],[61]. Lastly, Noble et al[58] 
conducted a cross-sectional review of PLWH with comorbid HTN in a secondary healthcare 
settings in Birmingham, United Kingdom. Findings showed that 63% (N=36) had controlled BP.  
 
In summary, patients attending model 4 of integrated care are reported to demonstrate high rates 
of NCD control similar to HIV-uninfected populations in comparable settings. However, neither 
key HIV outcomes, outcomes before integration, nor comparison with patients in non-integrated 
care, were reported in all three studies.
Table 2: Descriptive characteristics of selected articles 
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HTN and DM 
offered to PLWH 
1 N/A PLWH, N=854  
Of these, 
n=223 had  
comorbid HTN 
and n=108 had 
DM 
Cross-sectional ▪ Prevalence of HTN and DM was 26% 
and 13% respectively 
▪ 90% of PLWH and hypertension met   
ADA† target for BP  
▪ 59% of PLWH and DM met ADA 
target for HbA1c  
▪ Adherence to medication and viral 





















▪ Among those screened, 47.8% had 
HTN 
▪ Among 1649, 98.5% were initiated on 
ART, 70.7% were retained into care, 
and 90.3% were suppressed 
▪ Of the 1431 patients with HIV alone, 
1408 (98.4%) were initiated on ART, 
1005 (71.4%) were retained in care, 
100% of these were monitored and 906 
(90.2%) were controlled 
▪ Among PLWH with HTN, 99.5% were 
initiated on ART, 65.9% were retained, 
91.6% were suppressed and 24.3% had 
controlled BP‡. HIV outcomes were 















1 N/A 4278 PLWH, of 
which 
1840 had HTN 
Cross-sectional ▪ 88% on ART; 67% with suppressed VL 
(viral load less than 200 copies/mL) 
▪  Among 3906 with documented recent 
CD4, mean CD4 was 468 cells /µL  
▪ Prevalence of HTN was 43% 
▪ Of the PLWH with HTN, 75% were 
being treated; and 57% had controlled 
BP 
▪ No data reported on retention in care 
and adherence due to cross-sectional 
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DM only =2638 
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▪ 87.7% of HIV-infected were retained, 
9.3% died and 3% lost to follow up 
▪ Median CD4 count rose from 53 to 316 
cells/µL 
▪ 29 % lost to follow up 
 ▪ Median HbA1c fell from 11.5% to 
8.6%, 57% had HbA1c ≤ 9%  
▪ 68% of HTN had BP ≤160/90 after 6 
months of regular treatment 
▪ Adherence and viral suppression rates 
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through MACs 
3 12 Total of 1432 
were enrolled in 
MACs 
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People with HTN 
n = 352, 
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▪ Loss to follow up was 3.5% overall 
▪ High compliance to medical check-ups 
(99%) 
▪ Markers of control of HIV and HTN or 
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199 had HTN 
and only 89 were 
Prospective 
cohort 
▪ 48% of visits had controlled BP among 
PLWH in the entire follow up period 
▪  46% of visits had controlled BP among 
people not living with HIV  
▪ HIV-infected patients were more likely 
than uninfected patients to have 
linked to care at 
base line. 
32,633 were HIV 
negative, of these 
4355 had HTN 
and 1949 were 
linked to care at 
base line 
controlled blood pressure at follow-up 
visits (aOR 1.28; 95% CI 1.00–1.77) 
▪ NCD care was interrupted with 
significant hypertension drug stock 
outs 
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▪ Patients at intervention facilities had 
6% greater likelihood of CD4 >350 
cells/µL than comparison facilities 
(coefficient = 0.057; 95% CI: 0.056 to 
0.058; P < 0.001) 
▪ Patients at pilot facilities had 1.0% 
greater likelihood of controlled BP 
(coefficient = 0.010; 95% CI: 0.003 to 
0.016; P = 0.002). 
▪  Viral suppression, retention to care 
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▪ For PLWH and HTN, median systolic 
blood pressure (SBP) and interquartile 
range (IQR) reduced from 151 (136-
164) mmHg to 143 (129-159) mmHg 
while diastolic blood pressure (DBP) 
and IQR, reduced from 97 (86-105) 
mmHg to 85 (74-95) mmHg. 
▪ For PLWH and DM, mean HbA1c at 
last visit was 8.2% whereas among 
those with DM only mean HbA1c was 
8.8% 
▪ For those with HTN only, median 
SBP(IQR) reduced from 160 (144–
177) mmHg to 141 (129–158) mmHg 
while DP(IQR) reduced from 100 (90–
110) mmHg to  
87 (75–95) mmHg. 



















▪ Less than 50% attained ADA 
guidelines[59] for HbA1c  
▪ Glycaemic control was similar to 
findings in HIV-uninfected 
population[62],[63] 







UK   
 
 Treatment for 
HTN offered to 
PLWH and HTN 
4 N/A PLWH plus 
hypertension, 
n=36 
Cross-sectional ▪ 85% new or known hypertensive 
▪ 63% had controlled BP 
▪ Average decrease in 10-year 
cardiovascular risk was 39% (range 8% 
to 74%). 
▪ All patients rated the clinic as good or 
great on all aspects and were happy 
with the care received.  











care to PLWH 




▪ Baseline CD4 count was 516 
cells/µL+/-314 cells/µL 
▪ 72% had baseline viral load < 75 cells 
/mL 
▪ No HIV outcomes reported at the end 
of follow up 
 
▪ Mean HbA1c at baseline = 7.3% +/- 1.9 
%  
▪ 54% had HbA1c < 7%, and 72% had 
HbA1c < 8% at end of follow up 
▪ Rates of glycaemic control were 
similar to  results among HIV-
uninfected population (30%-
44%)[60],[61] 
▪ Mean SBP at baseline was 131 +/-17 
mmHg,  
▪ Mean DBP at baseline was 79 +/-10 
mmHg 
▪ 56% met ADA blood pressure goals at 
end of follow up 
* Model 1: Integration of NCD screening and treatment services into established HIV centres; Model 2: Integration of HIV screening and treatment services into established 
NCD centres; Model 3: simultaneous integration of HIV and NCD services at integrated health centres. Model 4: Integration of NCD and HIV care for particularly multi-
morbidity patients. This could be offered at an individual level or group level in form of medical adherence clubs for stable patients  
†ADA = American Diabetes Association, targets BP<140/90 and HbA1c < 7%. ‡ controlled BP means BP <140/90.95% CI means 95 percent confidence interval 
4. Discussion 
 Studies included in our review sought to evaluate long- term patient outcomes in various 
models of integrated HIV and NCD care. Eleven studies were identified and of these, 3 
reported outcomes in model 1 of integrated care[49,50,57], 5 reported outcomes in model 
3[23,51–54] and 3 reported outcomes in model 4 of integrated care[55,56],[58]. No study 
was found that reported outcomes in model 2 of integrated care. Results from three model 1 
studies showed that, after receiving integrated care, patients achieved high rates of control 
of their comorbidities[49,50,57]. Furthermore, HIV-related outcomes in one study were 
found to be similar among comorbid and non-comorbid PLWH[53]. This may suggest that 
when managed appropriately, comorbid PLWH can attain equally high levels of HIV control 
comparable to PLWH with no comorbidities. However, even though these studies reported 
high rates of HIV and NCD control after integration, a noteworthy finding was that none of 
these studies included a comparator group e.g. co-morbid PLWH attending non-integrated 
care.  As such, it is not known if the reported treatment outcomes in this model of care are 
higher than treatment outcomes in a non-integrated setting.  
 Simultaneous integration of NCD and HIV services (model 3) also appeared to confer clinical 
benefits to PLWH. Ameh et al[23]  showed that participants who attended integrated 
primary care facilities were found to have higher likelihood of control of their immune status 
as well as NCD compared to participants who never utilized integrated care. This was the 
only study identified that demonstrated that IC may have a positive effect on patient 
outcomes using a well-defined comparator group. However, while NCD outcomes were 
reported, the absence of HIV outcomes such as viral load suppression in most model 3 
studies means the effect of this model on HIV control remains unknown. 
Studies in our review also reported outcomes after integrating care for PLWH with comorbid 
DM or HTN (model 4)[55,56,58]. It is encouraging to note that multi-morbid patients who 
attended this form of integrated care achieved good clinical control of their comorbidities at 
rates similar to HIV-uninfected populations in their settings[60,61],[62,63]. However, 
similar to studies that reported patient outcomes in model 3, HIV-related outcomes were not 
reported in these studies. Consequently, it also remains unknown if this model of care is 
more effective for control of HIV among multi-morbid patients. Furthermore, these studies 
also did not include a control group to which patient outcomes after integration could be 
compared. Comparisons could take the form of before/after integration studies with the 
same multi-morbid PLWH or a comparison with multimorbid PLWH who received non-
integrated care.   
Overall, model 4 of integrated care appeared to confer the most benefit compared to the rest 
of the models as evidenced by relatively higher rates of clinical control of multi-morbidity 
among PLWH in spite of methodological challenges elucidated above. 
Patient outcomes among PLWH without NCD morbidities receiving ART care through 
adherence clubs (MACs) have been extensively described in literature. However, our review 
confirms lack of evidence on the effectiveness of integrated MACs (that include HIV and NCD 
care) for multimorbid PLWH who have more complex healthcare needs. Our review further 
highlights paucity of evidence from sub-Saharan Africa, where the burden of HIV and NCD 
syndemic is greatest, with only 4 studies identified[23,51–53]. Given that more than two 
thirds of PLWH live in sub-Saharan Africa[64], studies evaluating effectiveness of integrated 
HIV and NCD care are urgently needed in this setting to guide healthcare policy.  
To our knowledge, this is the first review to assess evidence on long-term patient outcomes 
in the context of various integrated  HIV and NCD models  of care; and we highlight the 
potential to  leverage  resources from HIV service platforms to  provide effective integrated 
chronic disease care[44,65,66].  
5. Conclusion 
The potential to leverage existing HIV infrastructure to provide NCD care to multimorbid 
patients without jeopardizing quality of care is a key consideration for health service 
delivery, particularly in high HIV-burden settings undergoing rapid epidemiological 
transition with a rise in NCD co-morbidity. Our review has identified evidence on integration 
of HIV/NCD care across diverse models of care, and the potential for integration to 
contribute to desired long-term patient outcomes. However, we highlight the urgent need 
for high quality research, including clinical trials with defined comparator groups to robustly 
investigate the clinical impact of integrated models of care on multimorbid HIV/NCD 
outcomes.   
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Abstract 
 Background: The growing burden of HIV and non- communicable disease (NCD) syndemic 
in Sub Saharan Africa, has necessitated introduction of integrated models of care in order to 
leverage existing HIV care infrastructure for NCDs. However, there is paucity of literature on 
long term treatment outcomes for multimorbid patients attending integrated care. We 
describe long term treatment outcomes among multimorbid patients who attended 
integrated ART and NCD clubs (IC), a novel model of care piloted in 2014 by the Western 
Cape Government in South Africa. 
Methods: We followed up multimorbid patients for 12 months, who enrolled for IC at 
Matthew Goniwe and Town II clinics before September 2016.Median adherence proportions, 
HIV viral suppression and retention rates were calculated at 12 months before and after IC 
enrolment. Rates for achieving targets for blood pressure and glycosylated hemoglobin were 
determined at 12 months prior, at IC enrolment and at 12 months post IC enrolment. We 
describe demographic and clinical variables among all patients at IC enrolment and used 
multivariable logistic regression to evaluate for predictors of NCD control 12 months post IC 
enrolment. 
Results: As of 31 August 2017, 247 patients in total had been enrolled into IC for at least 12 
months.  Of these, 221 (89.5%) had hypertension, 4 (1.6%) had diabetes mellitus and 22 
(8.9%) had both in addition to HIV. Adherence was maintained before and after IC enrolment 
with median adherence proportions of 1 (IQR 1-1) and 1 (IQR 1-1) respectively. HIV viral 
suppression rates were 98.6%, 99.5% and 99.4% at the three time points respectively. 
Retention in care was high with 6.9% lost to follow up at 12 months post IC enrolment. 
Optimal blood pressure control was achieved in 43.1%, 58.9% and 49.4% of participants 
whereas optimal glycaemic control was achieved in 47.4%, 87.5% and 53.3% of diabetic 
participants at the three time points respectively. Multivariable logistic analyses showed no 
independent variables significantly associated with NCD control. 
Conclusion 
Multimorbid people living with HIV achieved high levels of HIV control in integrated HIV and 














South Africa has one of the world’s largest HIV burdens, with an HIV prevalence of 12%[1]. 
Consequently, it hosts the largest antiretroviral  treatment (ART) program in the world[2], 
with 3.4 million patients receiving ART care at no individual cost[3].  Since the advent of 
effective ART, HIV has become a chronic, manageable illness, with lifespan approaching that 
of HIV-uninfected persons[4]. This increased lifespan, along with the aging effect of HIV and 
drug interactions[5,6], has resulted in people living with HIV (PLHIV) to be at risk of 
developing lifestyle related non-communicable diseases (NCDs), thus increasing the burden 
of multi-morbidity (MM). 
Previous research has shown that there is a significant burden of MM in South Africa with 
prevalence estimates ranging from 22.6% to 48.4%[7,8]. A study investigating MM in 
Khayelitsha, Western Cape (the setting of this study), found a high prevalence of comorbid 
hypertension and diabetes associated with HIV amongst patients on ART[8]. This dual 
epidemic of communicable and non-communicable diseases will put strain on the current 
health system which is ill equipped to cope with the inherent complexity of MM[9]. The high 
comorbidity among people living with HIV (PLHIV) highlights the need to integrate care of 
these conditions along with routine ART management. PLHIV without an NCD diagnosis 
attend regular ART medical adherence clubs (MACs) which comprise 25-30 PLHIV who have 
been on ART for at least 6 months with suppressed viral loads (VL). MACs involve both task-
shifting and decentralization of care at primary health care level and have been shown to 
decongest facilities[10], improve retention in care[11], maintain virologic 
suppression[12],to be cost effective[13] and  acceptable to both patients and health care 
workers[14].  
In response to the rising burden of MM, some clinics under The Western Cape Government 
have sought to achieve integration; piloting a novel model of care that adapts the MAC model 
and integrates HIV and NCD care (IC). The structure and eligibility for the IC is similar with 
the inclusion of a diagnosis of NCD such as Diabetes Mellitus (DM)or hypertension (HTN) or 
both (DMHTN). The standard of care for a MAC attendee who has comorbid NCD comprises 
attending a MAC club for ART care and a different outpatient appointment for NCD care often 
on a different day and sometimes, a different facility. While long term patient outcomes 
among PLHIV attending MACs have been well described[11,12,15,16] , there has not been a 
formal evaluation of long term patient outcomes among PLHIV attending this model of care 
since its adoption in Cape Town, South Africa. These long-term outcomes include, but are not 
limited to, medication adherence, retention in care, loss to follow up, HIV viral suppression 
and NCD control. Thus, it is not known if IC improves or at least maintains desired clinical 
outcomes compared to MACs and separate NCD care in PLHIV. Such evidence is needed to 
inform health program managers and policy makers in order to adopt, implement and scale 
up IC for multi-morbid PLHIV globally. Therefore, in this study we sought to assess clinical 
outcomes in patients with HIV and comorbid DM and/or HTN before and after 12 months of 
receiving IC at two primary health care clinics in Cape Town, South Africa.  
2. Methods 
2.1  Study setting and design 
We conducted a review of clinical outcomes for PLHIV  before and  after attending IC at two 
clinics (Mathew Goniwe and Town II Primary Health Care facilities) in Cape Town, South 
Africa. Patients had comorbid HTN and/or DM and enrolled into IC before September 2016. 
The study was approved by the University of Cape Town, Faculty of Health Sciences Human 
Research Ethics committee (HREC Ref no: 497/2019).  
2.2  Study population 
Mathew Goniwe and Town II are health facilities under the governance of the City of Cape 
Town Health Department. They are based in the peri-urban township of Khayelitsha which 
has a population of approximately 500,000[17] and estimated antenatal prevalence of 
37.1%[18]. Patients were adults over 18 years old, had documented HIV-infected status, 
documented diagnosis of DM or HTN or both and had attended MACs before they were 
enrolled into IC at the two clinics prior to September 2016. Clinical procedures routinely 
undertaken in MAC and IC clubs are summarized in Supplementary Table 1. 
Supplementary Table 1: Adherence club procedures 
 ART adherence club (MAC)     Integrated Club (IC) 
Club formation 
Approximately 25 patients are recruited into a club 
simultaneously and initiated into the club process together. 
Club admission criteria HIV infected and stable – at 
least 6 months on ART and 
suppressed viral load (VL) 
HIV infected with DM and/or HTN 
and stable – at least 6 months on 
ART and suppressed VL. Blood 
pressure (BP) <140/90mmHg and 
HbA1c†< 9%  
Number of Club visits per 
year 
Total = 5  
• 3 medication collections 
• 1 medication collection and clinical examination 
• 1 medication collection and phlebotomy 
Bloods tests conducted at 
phlebotomy visit  
Viral Load and safety bloods  
(Liver function, renal 
function and full blood 
count depending on ART 
regimen) * 
Viral Load and safety bloods 
(Liver function, renal function 
and full blood count depending 
on ART regimen 
HbA1c) **  
Creatinine ** 
 
Procedures at each clinical 
visit 
Weight, BP, Tuberculosis symptoms screen and ART side 
effects screen, HIV and health education and adherence 
counselling at each visit by lay-counsellor***  
Staff providing care Lay-counsellor for medication collections 
Professional Nurse practitioner for clinical examination and 
phlebotomy 
Medical officer to review complicated patients 
† HbA1c = glycosylated heamoglobin 
*Based on provincial ART guidelines[19] 
**Based on Primary Care “PACK” guidelines[20] 
***No specific NCD counselling for comorbid patients provided. 
 
2.3  Sampling and statistical power 
All adult patients who attended IC at the two pilot sites and met the inclusion criteria were 
included in the study. As there are no published studies that have investigated patient 
outcomes among comorbid PLHIV attending IC, we enrolled all patients registered in IC clubs 
in our study.  
2.4  Data collection  
Patients with comorbid diagnosis of HTN, DM or both (DMHTN) were identified from the IC 
club registers and clinic folders. Outcome measures (BP, VL, and HbA1c) were extracted from 
electronic and paper clinic records. Anonymized data were captured onto a RedCap 
electronic database by a trained study team.  
Patient demographic characteristics (age, sex), anthropometric measures (weight, height), 
disease-related (NCD diagnoses, WHO stage at HIV diagnosis, CD4 count at HIV diagnosis, 
time since HIV diagnosis, duration on ART, time since NCD diagnosis), IC club-related (IC 
club registration date, IC clinic) variables were extracted.  Clinical and adherence variables 
were also extracted. Adherence variables included number of scheduled and missed 
medication collection visits 1-year before and 1-year after IC registration. Clinical variables 
extracted included BP, VL and HbA1c measurements at 1-year before IC enrolment, at IC 
enrolment and at 1-year post IC enrolment. Patient outcomes were assessed from 1-year 
prior to IC enrolment up until 31 August 2017.  
2.5  Definition of outcome variables 
Adherence 
Prior to IC enrolment, we used medication collection as a surrogate for adherence. After IC 
enrolment, adherence to club visits, extracted from club registers was used as a surrogate 
for adherence. Good adherence was defined as proportion of attended visits of > 80%, 
according to WHO classification of adherence to long term therapy [21].   
Clinical control 
HIV control was defined as having a viral load  of < 1000 copies/ml [19] whereas NCD control 
was defined by the Society of Endocrinology, Metabolism and Diabetes of South Africa 
(SEMSA) targets for  BP  (BP < 140/90mmHg)  and glycosylated hemoglobin (HbA1c < 7.5%) 
among diabetics[22]. 
2.6  Statistical analysis  
 We pooled participant data from both clinics for analysis purposes. Categorical variables 
were described using frequencies and proportions, normally distributed continuous 
variables using means and 95 percent confidence intervals(95% CI), and non-parametric  
continuous variables using medians and interquartile ranges. Adherence to scheduled 
appointments was calculated as the proportion of appointments attended by every 
participant from  12 months prior to IC enrolment  up to the point of IC enrolment, and from 
IC enrolment  to 12 months later. Median adherence proportions were calculated for the 12 
months prior to IC enrolment and 12 months post IC enrolment and compared using the 
Wilcoxon signed rank test. 
 
The proportion of comorbid participants  with optimally controlled NCD according to SEMSA 
targets  was calculated cross-sectionally for three time points: (i) at  12 months before IC 
enrolment, (ii) at IC enrolment and (iii) at 12 months post IC enrolment. The proportions of 
comorbid participants with  optimally controlled NCD at IC enrolment and at 12 months post 
IC  enrolment  were compared using the Chi-squared test under the null hypothesis that IC 
enrolment maintains or improves clinical control of comorbidity.  
 
Univariate logistic regression was used to explore factors associated with comorbidity 
control and crude odds ratios calculated to identify independent variables that yielded a p-
value of ≤0.2. These variables were used to build a multivariate logistic model to estimate 
adjusted odds ratios and 95% confidence intervals for predictors of clinical control of NCD, 
with the outcome variable (NCD control) categorised as 1 if HTN or DM or both, were 
optimally controlled at 12 months post IC enrolment and as 0 if otherwise.  
 
Significance testing was performed  using 2-sided p-values at α of 0.05.All statistical analyses 
were conducted in STATA 15.0 (Stata Corp LP, College Station, TX). 
3. Results 
As of 31 August 2017, a total of 247 patients had been enrolled into IC clubs for at least 12 
months at Matthew Goniwe and Town II primary health care facilities (Table 1). There were 
no significant differences in demographic and clinical characteristics between patients at the 
two facilities at baseline, with the exception of duration with NCD and median CD4 count at 
HIV diagnosis. Patients who received care at Mathew Goniwe had a relatively higher median 
CD4 count at HIV diagnosis compared to Town II patients (Table 1).  In addition, patients 
who received care at Town II had relatively more recent diagnosis of NCD compared to 
patients who received care at Matthew Goniwe facility (Table 1). 
Table 1 
Demographic and clinical characteristics of study participants at baseline 
Variable *  
Matthew Goniwe 
 (n=71)  
 Town II 
(n=176)  
Total 
(N=247)  p-value    
Age (years), mean± SD† 48.35±8.43  45.99±8.65 46.67±8.64 0.0514 
Sex, Male 18(25.35)  41(23.30) 59(23.89) 0.8651 
Comorbidity      
DM 0(0)  4(2.27) 4(1.62)  
HTN 63(88.73)  158(89.77) 221(89.47)  
DMHTN 8(11.27)  14(7.95) 22(8.91) 0.326 
Time with NCD (years)      
0-5 43(65.15)  124(94.66) 167(84.77)  
6--10 20(30.30)  4(3.05) 24(12.18)  
> 10 3(4.55)  3(2.29) 6(3.05) <0.001 
Time with HIV (years)      
0-5 31(44.29)  91(58.71) 122(54.22)  
6--10 28(40.00)  49(31.61) 77(34.22)  
> 10 11(15.71)  15(9.68) 26(11.5) 0.113 
Time on ART (years)      
0-5 48(67.61)  139(78.98) 187(75.71)  
6--10 22(30.99)  36(20.45) 58(23.48)  
> 10 1(1.14)  1(0.57) 2(0.81) 0.155 
WHO stage      
0 14(19.72)  60(34.09) 74(29.96)  
1 21(29.58)  53(30.11) 74(29.96)  
2 28(39.44)  43(24.43) 71(28.74)  
3 6(8.45)  15(8.52) 21(8.50)  
4 2(2.82)  5(2.84) 7(2.83) 0.103 
CD4 count at Diagnosis‡      
<350 40(61.54)  89(67.94) 129(65.82)  
≥ 350 25(38.46)  42(32.06) 67(34.18) 0.374 
Median CD4(IQR)‡ 88(35-123)  47.5(1-108) 61(11-116) 0.0053 
 
*characteristics are described as n (%) where n is number of participants with the characteristic and % is percentage of the study 
population with the given characteristic,† SD =standard deviation of the mean, HTN=Hypertension, DM= Diabetes Mellitus type 2,DMHTN= 
dual diagnosis of HTN and Diabetes Mellitus type 2, NCD = non -communicable disease  which implies  either DM or HTN  or both in  this 
case and ‡ = cells/µL 
 
3.1  Patterns of multi-morbidity and treatment  
Of the 247 patients, 221 (89.5%) had comorbid HTN, and 22 (8.9%) had a triple burden of 
HIV, DM and HTN. A small number ,4 (1.62%), of patients had DM only.   The median time 
with comorbidity regardless of type of NCD, was 3 (IQR (2-4)) years among 197 patients 
with available data on duration since NCD diagnosis. 
Among those with HTN, 95.48% received pharmacological therapy. The majority of patients 
were being treated with Hydrochlorothiazide (82.93%), Enalapril (9.95%) and Amlodipine 
(6.6%), All patients with comorbid DM were treated with oral anti-glycaemic agents. 
Pharmacological therapy for HTN among patients with HTN and DM was similar to that 
among patients with HTN only.  
3.2  Adherence to medication 
Median adherence proportions (proportion of scheduled visits attended) and their 
interquartile ranges before and after IC enrolment were 1 (IQR 1-1) and 1 (IQR 1-1) 
respectively in which an adherence proportion of 1 meant that a participant had attended 
approximately all scheduled appointments. Therefore, high adherence to medication was 
maintained before and after attending IC. There was no significant difference in median 
adherence proportions before and after attending IC (p = 0.1334) either overall or by 
patterns of MM.   
 
Categorizing adherence as good or bad, there were equally high proportions of good 
adherence among patients before and after attending IC (91.90% and 90.28% respectively, 
p = 0.305). This observation also did not change when we sub-grouped our sample by 
patterns of MM. 
3.3  HIV control 
In our study population, 215/247 (87%) had documented viral load testing at 12 months 
prior to IC enrolment. Of these,212 (98.6%) were virally suppressed. Similarly, 212 patients 
had documented viral load testing at IC enrolment and 211 (99.5%) were virally suppressed. 
Likewise,164 had documented viral load testing 12 months after IC, of which 163 (99.4%) 
were virally suppressed. In addition,93% were retained into care at 1-year post IC enrolment 
with 6.9% lost to follow up. Thus, in our study population, HIV control was optimal and was 
maintained at 1-year post IC enrolment with high retention into care. HIV control did also 
not differ by patterns of MM. 
3.4  Blood Pressure control 
Mean Systolic Blood Pressure (SBP) was 139.9 95% CI (136.9-142.9), 132.1 95% CI (129.7-
134.6) and 136.7 95% CI (133.7-139.6) at 1-year before IC, at IC enrolment and 1-year post 
IC enrolment respectively. Likewise, mean Diastolic Blood Pressure (DBP) was 84.7 95% CI 
(82.7-86.6), 79.7 95% CI (78.23-81.23) and 80.1 95% CI (78.35-81.86) at 1-year before IC, at 
IC enrolment and 1-year post IC enrolment respectively (Figures 1 and 2). Thus, both   SBP 
and DBP decreased until IC enrolment and   increased at 1-year post IC enrolment, though 
not statistically significant. 
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In terms of Blood Pressure (BP) control, 43.4% 95% CI (34.6,50.5), 58.9% 95% CI (52.0,65.7) 
and 49.4% 95% CI (41.5,57.3) had optimally controlled BP at 1-year before IC enrolment, at 
IC enrolment and at 1-year post IC enrolment respectively. Thus, a large  proportion of our 
study population achieved BP control at IC enrolment ,however, BP control declined  by 9.5%  
at 1-year post IC (p = 0.0325 ).When we compared proportions of BP control 1-year post IC 
attendance among patients with HTN only against those with DMHTN, there was no 
significant difference in rates of BP control among the two patient groups (64.3 vs 47.6 
respectively, p = 0.1166). 
3.5  Diabetes control 
Mean glycosylated haemoglobin (HbA1c) among all patients with DM (either DM or DMHTN) 















1 year post IC
to IC enrolment, at IC enrolment and at 1-year post IC enrolment respectively (Figure 3). 
Thus, mean HbA1c at 1-year post IC enrolment increased slightly from mean HbA1c at IC 
enrolment even though not statistically significant (p = 0.3514).  
 
Proportions of diabetic patients with optimal glycaemic control were 47.4% 95% CI 
(24.5,71.1), 87.5% 95% CI (61.7,98.5) and 53.3% 95% CI (26.6,78.7) at 1-year, at enrolment 
into IC and at 1-year post IC enrolment respectively. Thus, the proportion of diabetic patients 
with optimally controlled DM 1-year post IC enrolment was significantly lower compared to 
the point of IC enrolment (p = 0.0180).  Thus, it can be seen that despite achieving high 
glycaemic control at IC enrolment, approximately 30% of our population did not maintain 
glycaemic control 1-year following IC attendance contrary to our hypothesis. 
Figure 3: Glycaemic control over time 
 
3.6  Predictors of control of comorbidity 
In univariate logistic regression models, CD4 count, time with NCD, adherence status and site 
for IC at baseline appeared to affect control of NCD at α = 0.2 level (Table 2). However, in our 
multivariate logistic model, none of these variables appeared to significantly affect control 
of NCD  12 months post IC enrolment at α = 0.05 (Table 2). 
Table 2 
Predictors of NCD control in addition to IC  
  Univariate Analyses Multivariate Analyses 
Characteristic OR† 95% CI P- value aOR‡ 95% CI P -value 
CD4 count(cells/µL) <350 1.00   1.00   
 ≥350 0.67 (0.35,1.27) 0.217 0.59 (0.29,1.18) 0.138 
Time with NCD (years) 0-5 1.00   1.00   
 6--10 0.27 (0.09,0.83) 0.022 0.35 (0.10,1.16) 0.087 
 >10  0.68 (0.12,3.79) 0.656 1.42 (0.22,9.25) 0.716 
Good adherence No 1.00   1.00   
 Yes 0.47 (0.19,1.19) 0.112 0.47 (0.16,1.38) 0.17 
Clinic site 
Matthew 
Goniwe 1.00      
 Town II 1.56 (0.85,2.87) 0.15 1.50 (0.71,3.16) 0.284 
Age group(years) <40 1.00      
 40-50 1.14 (0.55,2.34) 0.729    
 >50 1.05    (0.49,2.26) 0.906    
Sex Male 1.00      
 Female 1.09 (0.58,2.03) 0.794    
Comorbidity DM 1.00      
 DMHTN 0.46 (0.06,3.36) 0.447    
 HTN 1.00 (0.12,8.42) 1    
BMI category < 18.5 1.00      
 18.5–24.9 0.47 (0.026,8.52) 0.61    
 25.0–29.9 0.89 (0.05,15.44) 0.939    
 ≥30 0.54 (0.032,8.90) 0.666    
WHO stage 0 1.00      
 1 0.78 (0.39,1.56) 0.483    
 2 0.94 (0.48,1.87) 0.866    
 3 2.03 (0.76,5.41) 0.157    
 4       
Time on ART (years) 0-5 1.00      
 6--10 0.96 (0.51,1.79) 0.896    
 >10 1.97 (0.12,31.99) 0.634    
Time since HIV 
Dx(years)  0-5 1.00      
 6--10 1.26 (0.69,2.28) 0.443    
  >10  1.23 (0.51,2.96) 0.637       
† OR = unadjusted odds ratio, ‡ aOR = adjusted odds ratio 
 
4. Discussion 
Our study is the first to report treatment outcomes among PLHIV living with other NCDs 
(MM) attending   integrated NCD/ ART clubs piloted in Cape Town, South Africa.  Several 
studies have reported treatment outcomes in various models of integrated HIV and NCD care 
(scoping review by BG et al). However, only two studies have reported treatment outcomes 
among PLHIV with comorbid DM or HTN[23,24]. Moreover, no study, to our knowledge, has 
evaluated treatment outcomes among PLHIV with comorbid NCDs attending IC in particular. 
This study had several notable findings. Firstly, adherence to medication was high and 
sustained at 1-year of attending IC. On the same note, at 1-year post IC registration, 93% of 
our sample was retained in care with overall loss to follow up of 6.9%.      
Second, HIV control was sustained at 1-year post IC enrolment with optimal viral 
suppression of near 100%. This finding  is  reassuring in that the viral suppression, 
adherence  and retention  rates  are similar to those reported in ordinary MACs in this 
setting[13,15,25] .It shows good progress towards the UNAIDS 90:90:90 targets for HIV  
epidemic control  whereby at least 90% of PLHIV receiving ART should suppress their viral 
loads[26] . 
In addition, this finding also means that NCD care can be safely incorporated into HIV care 
programs without compromising HIV care, thus supporting the notion of leveraging HIV 
infrastructure for NCD care in the context of the rising NCD epidemic among PLHIV. Not only 
is integrated HIV and NCD care efficient in terms of optimizing utilization of resources, it has 
also been found to be convenient and acceptable to patients[27]. 
Thirdly, low NCD control rates were found before IC enrolment. They increased just before 
IC enrolment and declined at 1-year post IC enrolment. 
The reason for this finding is unclear. One possible reason is insufficient exposure to regular 
health promotion counselling after IC enrolment and resulting lifestyle modification post IC 
enrolment. Patients may have been more adherent to lifestyle modification just before IC 
enrolment in order to benefit from the convenience of IC and potentially laxed in their life 
style modification commitments upon enrolment into IC. Since NCD control is not just a 
product of taking medication but rather to a larger extent a product of life style modification 
regarding diet, smoking and physical exercise, laxity in commitment to life style modification 
may explain the lapse in NCD control post IC enrolment[ 28,29,30].  
The low rates of NCD control before IC enrolment show the burden of poorly controlled NCDs 
among PLHIV receiving disintegrated care. This has a negative impact on quality of life of 
PLHIV in that it increases risk of neurovascular events such as stroke and microvascular 
events such as renal and ophthalmic disease in addition to ART and HIV itself, thereby 
exacerbating mortality and morbidity among PLHIV. On the other hand, the higher rates of 
NCD control at IC enrolment in our study population show the potential of streamlined and 
intensified care in achieving greater NCD control among PLHIV with MM. 
After 1-year post IC enrolment, rates of BP and glycaemic control relate favourably with 
those found by Bury et al[23] and Oluwatoyin et al [24] among PLHIV with comorbid NCD in 
the USA where approximately 50 % of PLWH  with comorbid DM are reported to have 
achieved glycaemic control and 47% are reported to have   achieved BP control.  Our NCD 
control rates after attending IC  are also consistent with findings among patients who 
attended integrated NCD and HIV care in Uganda in which  a BP control rate of 46% was 
achieved  after attending integrated care for three years[31].On the other hand, our NCD 
control rates are way higher than control rates  reported among HIV -uninfected patients in 
Cape Town in which only 33% of patients with HTN had controlled their BP and 42% of 
diabetics  had achieved glycaemic control[32].   Thus, BP control after 12 months of attending 
IC in our sample was approximately 20% higher than that reported among HIV-uninfected 
individuals whereas glycaemic control was at least 10 % higher than that reported among 
HIV -uninfected individuals who also received care at public primary health care facilities in 
the same setting. This may be due to increased access to adherence counselling and retention 
support that PLHIV have over their HIV-uninfected counterparts as also observed in Uganda 
by Kwarisiima et al[31]. 
Our study had some limitations.  Variables which have been found to independently affect 
HTN and DM control such as income, level of education and lifestyle related factors (smoking, 
diet and exercise)[33,34] were not available from routinely collected patient data and hence 
were not included in data collection and analysis. As a result, we do not know the impact of 
these confounders on NCD treatment outcomes in our study population. In addition, our 
univariate logistic regression analyses showed that time with NCD, adherence status and 
clinic site at IC enrolment appeared to affect control of NCD at 1-year post IC enrolment, at 
α= 0.2 level. However, in our multivariate model, no variable at IC enrolment appeared to 
significantly affect NCD control 1-year post IC enrolment at α= 0.05. This could be partly due 
to small sample size (N=247) resulting into low power in our multivariate logistic model. In 
future  studies,  a  sample size of larger than 247 would be recommended to provide sufficient 
power for meaningful ascertainment of effect sizes. 
This study has implications for policy and practice. Our findings suggest that NCD and HIV 
care can be safely integrated. We therefore recommend scale-up and uptake of integrated 
HIV and NCD clubs to other parts of the country as well as to other settings with high HIV-
burden undergoing rapid epidemiological transition with a rise in NCD co-morbidity. 
However, models of integration  should not just provide a “one stop centre” where 
multimorbid people living with HIV access medication for both diseases. Instead, they should  
also incorporate holistic NCD care that includes continuous health promotive counselling for 
lifestyle modification in order to  achieve sustained NCD control. 
 
5. Conclusion 
Our study has demonstrated that PLHIV and NCD can sustain high levels of HIV control after 
attending integrated NCD and ART care clubs as evidenced by high levels of viral 
suppression, good retention into care and minimal loss to follow-up. This is evidence to 
suggest that integration of NCD care into routine HIV care in order to leverage the pre-
existing HIV infrastructure for NCD care is safe. High levels of NCD control can also be 
achieved in integrated care, however, intensified health promoting interventions upon 
enrolment into integrated care are needed to sustain NCD control in the long term. 
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